AIkido Pharma Inc. today announced that the Company has secured an early equity interest in privately-held Discord, Inc. (https://discord.com/), a social communications platform provider that is particularly popular with gamers.
Bloomberg Technology reported on March 14, 2022, that Discord “is interviewing bankers about going public as soon as this year.” (https://www.bloomberg.com/news/articles/2022-03-15/discord-is-said-to-interview-banks-for-possible-direct-listing). According to the Bloomberg report, “Discord, last valued by private investors at about $15 billion, is especially popular with gamers and young people. Its success caught the attention of potential suitors, including Microsoft Corp., which was rebuffed after offering $12 billion for it last year.” According to The Straits Times, Discord has also held discussions with Epic Games and Amazon.com in the past. (https://www.straitstimes.com/tech/tech-news/video-game-chat-app-discord-ends-takeover-talks-with-microsoft).
Anthony Hayes, CEO of AIkido, stated, “This investment fits well into our strategy to maximize opportunity for liquidity and monetization events for our shareholders. We believe the offer by Microsoft to buy the company bodes well for this investment, as does a potential near-term IPO.”
About AIkido Pharma Inc.
AIkido Pharma Inc. was initially formed in 1967 and is a biotechnology Company with a diverse portfolio of small-molecule anticancer and antiviral therapeutics. The Company’s platform consists of patented technology from leading universities and researchers, and we are currently in the process of developing an innovative therapeutic drug platform through strong partnerships with world renowned educational institutions, including The University of Texas at Austin and University of Maryland at Baltimore. Our diverse pipeline of therapeutics includes therapies for pancreatic cancer, prostate cancer. We are constantly seeking to grow our pipeline to treat unmet medical needs in oncology. The Company is also developing a broad-spectrum antiviral platform that may potentially inhibit replication of multiple viruses including Influenza virus, SARS-CoV (coronavirus), MERS-CoV, Ebolavirus and Marburg virus.
